Axim Biotechnologies Inc., of New York, said its development partner, Flintshire, U.K.-based Quay Pharmaceuticals Ltd., has obtained licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of Axim's Medchew Rx pharmaceutical chewing gum's family of products. Read More
DUBLIN – Shares in Abivax SA surged by more than 175 percent during trading Tuesday on news that its HIV maturation inhibitor, ABX-464, may be able to reduce viral reservoirs in HIV-infected patients who already have undetectable plasma viral load. Read More
Foamix Pharmaceuticals Ltd., of Rehovot, Israel, reported results from additional analyses of the recently completed phase III pivotal trials for lead candidate FMX-101 in moderate to severe acne. Read More
Exelixis Inc., of South San Francisco, reported its first profitable quarter, with net revenues of $68.9 million from its cabozantinib franchise – an increase of 33 percent from the fourth quarter of 2016 – and net income of $16.7 million. Read More
Magenta Therapeutics Inc., of Cambridge, Mass., completed a $50 million series B financing, about five-and-a-half months after announcing the close of a $48.5 million A round in November 2016. Read More
HONG KONG – China's leading vaccine maker, Sinovac Biotech Ltd., has postponed its 2016 annual report while it investigates allegations made by U.S. investment management company Geoinvesting LLC that its CEO may have been involved in bribing a CFDA official to speed up drug approvals. Read More
Amag Pharmaceuticals Inc. missed the consensus mark on first-quarter sales of Makena (hydroxyprogesterone caproate) but nailed all the primary and secondary endpoints in the phase III trial testing the firm's approved Feraheme (ferumoxytol) compared to Injectafer (ferric carboxymaltose injection, Luitpold Pharmaceuticals Inc.) in adults with iron deficiency anemia (IDA). Read More
Patients with early stage Alzheimer's disease (AD) had epilepsy-like activity in the brain that was too subtle to be picked up with standard EEG recording methods, but could be detected with intracranial electrodes. The findings, which were published in the May 1, 2017, online issue of Nature Medicine, suggest that epilepsy can occur early in AD, and may contribute to both memory problems and neuronal damage without being clinically apparent. Read More
Following a dismal year-end 2016 showing that pushed shares of Gilead Sciences Inc. to a three-year low, analysts were looking for signs of a business turnaround in 2017. Alas, for the Foster City, Calif.-based biopharma, that proved not to be the case. Read More
